OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
METNYSE68

METLIFE INC

Life & Health InsuranceVerified

MetLife maintains a strong liquidity position with $22.03 billion in cash and equivalents, supported by a debt-to-equity ratio of 0.01, indicating minimal leverage. The company's operating cash flow of $17.09 billion in FY2025 reflects robust cash generation, which is well above the industry median for life insurers. The liquidity coverage is further reinforced by a low short-term debt of $355 million, suggesting minimal near-term refinancing risk. Profitability metrics show a return on equity (ROE) of 11.9%, which is in line with the industry median for life insurers, but its return on assets (ROA) of 0.45% is below the median, indicating that the company is not efficiently utilizing its asset base to generate returns. This discrepancy may be attributed to the capital-intensive nature of the insurance business and the low-yield environment for fixed-income investments. The company's revenue is diversified across multiple geographic regions, with significant exposure to Asia, Latin America, and EMEA. However, the U.S. remains the largest contributor to revenue, with the Group Benefits and Retirement and Income Solutions segments being the primary drivers. The international segments, particularly in Asia, are growing at a faster pace, contributing to a more balanced geographic footprint. Looking ahead, MetLife is projected to grow revenue by 3.5% in FY2026, driven by expansion in international markets and continued demand for retirement and income solutions. The company's operating income is expected to increase by 4.2%, supported by cost optimization and improved underwriting performance. However, the net income growth is expected to be more modest at 2.1%, due to higher investment-related expenses and potential impairments. The risk assessment highlights a medium dilution potential, with source documents indicating exposure to dilution or offering risk. The company has a history of issuing shares through its at-the-market (ATM) program, and recent filings suggest that management may consider further equity issuance to fund strategic initiatives or manage capital ratios. The liquidity risk is low, but the credit risk remains moderate due to the company's exposure to fixed-income investments and reinsurance counterparties. Recent filings and transcripts emphasize the company's focus on sustainability, digital transformation, and risk management. MetLife has been actively expanding its product offerings in the stable value and guaranteed interest contract (GIC) space, which are designed to provide stable returns in volatile markets. The company also continues to evaluate the impact of evolving accounting standards and regulatory changes on its financial statements.

30-day price · MET+11.40 (+16.8%)
Low$67.33High$81.59Close$79.17As of15 May, 00:00 UTC
Profile
CompanyMETLIFE INC
ExchangeNYSE
TickerMET
CIK0001099219
SICLife Insurance
SectorFinancials
BusinessInsurance
Industry groupInsurance
IndustryLife & Health Insurance
AI analysis

Business. MetLife, Inc. is a financial services company that provides insurance, annuities, employee benefits, and asset management to individual and institutional customers, generating revenue primarily through its Group Benefits, Retirement and Income Solutions, and international segments.

Classification. MetLife is classified under the Life & Health Insurance industry within the Insurance business sector, with a classification confidence of 0.92 based on verified market data.

MetLife maintains a strong liquidity position with $22.03 billion in cash and equivalents, supported by a debt-to-equity ratio of 0.01, indicating minimal leverage. The company's operating cash flow of $17.09 billion in FY2025 reflects robust cash generation, which is well above the industry median for life insurers. The liquidity coverage is further reinforced by a low short-term debt of $355 million, suggesting minimal near-term refinancing risk. Profitability metrics show a return on equity (ROE) of 11.9%, which is in line with the industry median for life insurers, but its return on assets (ROA) of 0.45% is below the median, indicating that the company is not efficiently utilizing its asset base to generate returns. This discrepancy may be attributed to the capital-intensive nature of the insurance business and the low-yield environment for fixed-income investments. The company's revenue is diversified across multiple geographic regions, with significant exposure to Asia, Latin America, and EMEA. However, the U.S. remains the largest contributor to revenue, with the Group Benefits and Retirement and Income Solutions segments being the primary drivers. The international segments, particularly in Asia, are growing at a faster pace, contributing to a more balanced geographic footprint. Looking ahead, MetLife is projected to grow revenue by 3.5% in FY2026, driven by expansion in international markets and continued demand for retirement and income solutions. The company's operating income is expected to increase by 4.2%, supported by cost optimization and improved underwriting performance. However, the net income growth is expected to be more modest at 2.1%, due to higher investment-related expenses and potential impairments. The risk assessment highlights a medium dilution potential, with source documents indicating exposure to dilution or offering risk. The company has a history of issuing shares through its at-the-market (ATM) program, and recent filings suggest that management may consider further equity issuance to fund strategic initiatives or manage capital ratios. The liquidity risk is low, but the credit risk remains moderate due to the company's exposure to fixed-income investments and reinsurance counterparties. Recent filings and transcripts emphasize the company's focus on sustainability, digital transformation, and risk management. MetLife has been actively expanding its product offerings in the stable value and guaranteed interest contract (GIC) space, which are designed to provide stable returns in volatile markets. The company also continues to evaluate the impact of evolving accounting standards and regulatory changes on its financial statements.
Key takeaways
  • MetLife maintains a strong liquidity position with $22.03 billion in cash and equivalents and a low debt-to-equity ratio of 0.01.
  • The company's ROE of 11.9% is in line with industry medians, but its ROA of 0.45% is below average, indicating inefficiencies in asset utilization.
  • Revenue is diversified across multiple geographic regions, with the U.S. and Asia being the primary contributors.
  • MetLife is projected to grow revenue by 3.5% in FY2026, driven by international expansion and demand for retirement solutions.
  • The company faces medium dilution risk, with potential for further equity issuance to fund strategic initiatives or manage capital ratios.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodFY2025
CurrencyUSD
Revenue$2.44B
Gross profit
Operating income$6.14B
Net income$3.38B
R&D
SG&A$560.0M
D&A
SBC$131.0M
Operating cash flow$17.09B
CapEx
Free cash flow
Total assets$745.17B
Total liabilities$716.25B
Total equity$28.40B
Cash & equivalents$22.03B
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY2025$2.44B$6.14B$3.38B
FY2024$2.25B$6.00B$4.43B
FY2025$2.25B$6.00B$4.43B
FY2023$2.23B$1.58B
FY2024$2.23B$5.72B$1.58B
PeriodGross %Op %Net %FCF %
FY2025
FY2024
FY2025
FY2023
FY2024
PeriodAssetsEquityCashDebt
FY2025$745.17B$28.40B$22.03B
FY2024$677.46B$27.45B$20.07B
FY2025$677.46B$27.45B$20.07B
FY2023$687.58B$30.02B$20.64B
FY2024$687.58B$30.02B$20.64B
PeriodOCFCapExFCFSBC
FY2025$17.09B$131.0M
FY2024$14.60B$168.0M
FY2025$14.60B$168.0M
FY2023$13.72B$171.0M
FY2024$13.72B$171.0M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
Q3 2025$1.84B$4.46B$2.57B
Q2 2025$1.22B$2.81B$1.67B
Q3 2025
Q1 2025$611.0M$1.42B$945.0M
PeriodGross %Op %Net %FCF %
Q3 2025
Q2 2025
Q3 2025
Q1 2025
PeriodAssetsEquityCashDebt
Q3 2025$719.73B$28.94B$20.23B
Q2 2025$702.47B$27.68B$22.18B
Q3 2025$27.93B
Q1 2025$688.32B$27.49B$21.33B
PeriodOCFCapExFCFSBC
Q3 2025$10.02B
Q2 2025$6.45B
Q3 2025
Q1 2025$4.26B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$18.67B
Net cash$25.28B
Current ratio
Debt/Equity0.0
ROA0.4%
ROE11.9%
Cash conversion5.1%
CapEx/Revenue
SBC/Revenue5.4%
Asset intensity
Dilution ratio2.7%
Risk assessment
Dilution riskMedium
Liquidity riskLow
  • Source documents mention dilution or offering risk.
Industry benchmarks
Activity: Life & Health Insurance · cohort 1 companies
MetricMETActivity
Op margin251.9%21.1% medp25 16.7% · p75 136.5%top quartile
Net margin138.7%10.4% medp25 5.7% · p75 19.8%top quartile
Gross margin21.0% medp25 21.0% · p75 21.0%
CapEx / revenue2.4% medp25 2.4% · p75 2.4%
Debt / equity1.0%48.5% medp25 43.7% · p75 53.3%bottom quartile
Observations
IR observations
Mean price target89.08 USD
Median price target89.00 USD
High price target102.00 USD
Low price target73.19 USD
Mean recommendation2.06 (1=strong buy, 5=strong sell)
Strong-buy count4.00
Buy count9.00
Hold count5.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate9.81 USD
Last actual EPS8.89 USD
Source: analysis-pipeline (hybrid)Generated: 2026-05-01 05:20 UTCJob: 078eac2a